Bausch Health Cos Other Operating Income or Expenses 2010-2024 | BHC

Bausch Health Cos other operating income or expenses from 2010 to 2024. Other operating income or expenses can be defined as the aggregate amount of all operating expenses either too small to report separately or that cannot be standardized into another Zacks field.
Bausch Health Cos Annual Other Operating Income or Expenses
(Millions of US $)
2023 $-28
2022 $-35
2021 $-373
2020 $-616
2019 $-1,426
2018 $29
2017 $642
2016 $-60
2015 $-272
2014 $277
2013 $-294
2012 $-210
2011 $-29
2010 $-91
2009 $-12
Bausch Health Cos Quarterly Other Operating Income or Expenses
(Millions of US $)
2024-09-30 $-225
2024-06-30 $-20
2024-03-31
2023-12-31 $-28
2023-09-30 $-60
2023-06-30 $83
2023-03-31 $-23
2022-12-31 $-29
2022-09-30 $-4
2022-06-30
2022-03-31 $-2
2021-12-31 $-44
2021-09-30 $183
2021-06-30 $-542
2021-03-31 $30
2020-12-31 $-444
2020-09-30 $-18
2020-06-30 $-118
2020-03-31 $-36
2019-12-31 $-1,409
2019-09-30 $-13
2019-06-30 $-28
2019-03-31 $24
2018-12-31 $3
2018-09-30 $34
2018-06-30 $6
2018-03-31 $-14
2017-12-31 $-239
2017-09-30 $563
2017-06-30 $68
2017-03-31 $250
2016-12-31 $-62
2016-09-30 $-10
2016-06-30 $39
2016-03-31 $-27
2015-12-31 $-6
2015-09-30 $-41
2015-06-30 $-198
2015-03-31 $-27
2014-12-31 $20
2014-09-30 $226
2014-06-30 $-2
2014-03-31 $33
2013-12-31 $-96
2013-09-30 $-176
2013-06-30 $-13
2013-03-31 $-10
2012-12-31 $-104
2012-09-30 $-10
2012-06-30 $-75
2012-03-31 $-20
2011-12-31 $-4
2011-09-30 $-16
2011-06-30 $-6
2011-03-31 $-2
2010-12-31 $-17
2010-09-30 $-67
2010-06-30 $-8
2010-03-31
2009-12-31 $-6
2009-09-30
2009-06-30 $-6
2009-03-31 $-0
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $3.358B $8.757B
Bausch Health Companies Inc. develops, manufactures and markets a wide array of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products along with medical devices such as contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices in the therapeutic areas of eye-health, gastroenterology (GI), and dermatology.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.384B 6.36
Dr Reddy's Laboratories (RDY) India $12.329B 23.59
BridgeBio Pharma (BBIO) United States $4.629B 0.00
Amphastar Pharmaceuticals (AMPH) United States $2.294B 13.79
Supernus Pharmaceuticals (SUPN) United States $2.089B 28.44
Taysha Gene Therapies (TSHA) United States $0.490B 79.67
Personalis (PSNL) United States $0.278B 0.00
Assembly Biosciences (ASMB) United States $0.105B 0.00
Sol-Gel Technologies (SLGL) Israel $0.016B 0.00
Evoke Pharma (EVOK) United States $0.004B 0.00
Teligent (TLGT) United States $0.000B 0.00